分析癫痫患儿联合应用左乙拉西坦、奥卡西平治疗的疗效及安全性  

Analysis of the efficacy and safety of combined levetiracetam and oxcarbazepine in the treatment of children with epilepsy

作　　者：吴忠强[1] WU Zhong-qiang(Department of Pediatrics,Tai'an Maternal and Child Health Hospital,Tai'an 271000,China)

机构地区：[1]泰安市妇幼保健院儿科,271000

出　　处：《中国实用医药》2023年第19期103-106,共4页China Practical Medicine

摘　　要：目的探讨左乙拉西坦联合奥卡西平治疗癫痫患儿的效果及安全性。方法62例癫痫患儿,通过随机数字表法分为参照组和观察组,各31例。参照组患儿实施奥卡西平单独治疗,观察组患儿采取左乙拉西坦联合奥卡西平治疗。比较两组患儿临床效果、脑电图改善效果、不良反应发生情况及治疗前后认知功能、生活质量。结果观察组临床总有效率93.55%高于参照组的74.19%,差异有统计学意义(P<0.05)。观察组脑电图总改善率96.77%高于参照组的80.65%,差异有统计学意义(P<0.05)。观察组不良反应发生率3.23%低于参照组的19.35%,差异有统计学意义(P<0.05)。治疗后,观察组语言智商、操作智商、总智商评分分别为(49.11±0.81)、(49.35±0.45)、(99.35±0.64)分,均高于参照组的(47.31±1.24)、(47.21±2.25)、(97.10±2.05)分,差异有统计学意义(P<0.05)。治疗后,观察组认知功能、精力、药物影响、对发作的担忧、社会功能、情绪状况、自评生活质量、总体健康水平评分分别为(67.58±10.16)、(77.67±11.76)、(69.26±11.25)、(67.29±11.34)、(77.54±11.97)、(68.16±10.49)、(70.69±11.83)、(69.46±10.16)分,均高于参照组的(58.22±10.14)、(67.27±11.13)、(59.04±10.23)、(57.28±10.05)、(65.07±10.28)、(58.36±10.18)、(59.65±10.65)、(60.32±10.20)分,差异有统计学意义(P<0.05)。结论左乙拉西坦和奥卡西平联合治疗癫痫患儿疗效理想,脑电图痫样放电改善率较高,还可改善患儿认知功能及生活质量,具有较高的临床应用价值。Objective To discuss the effect and safety of combined levetiracetam and oxcarbazepine in the treatment of children with epilepsy.Methods A total of 62 children with epilepsy were divided into reference group and observation group according to the random numerical table,with 31 cases in each group.The reference group was treated with oxcarbazepine alone,and the observation group was treated with levetiracetam and oxcarbazepine.The clinical effect,electroencephalogram improvement effect,occurrence of adverse reactions,cognitive function and quality of life before and after treatment were compared between the two groups.Results The total clinical effective rate of the observation group was 93.55%,which was higher than that of 74.19%of the reference group,and the difference was statistically significant(P<0.05).The overall improvement rate of electroencephalogram in the observation group was 96.77%,which was higher than that of 80.65%in the reference group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 3.23%,which was lower than that of 19.35%in the reference group,and the difference was statistically significant(P<0.05).After treatment,the scores of verbal intelligence quotient,operational intelligence quotient,and total intelligence quotient in the observation group were(49.11±0.81),(49.35±0.45),and(99.35±0.64)points,which were higher than those of(47.31±1.24),(47.21±2.25),and(97.10±2.05)points in the reference group,and the differences were statistically significant(P<0.05).After treatment,the scores of cognitive function,energy,drug influence,worry about seizure,social function,emotional status,self-rated quality of life and general health in the observation group were(67.58±10.16),(77.67±11.76),(69.26±11.25),(67.29±11.34),(77.54±11.97),(68.16±10.49),(70.69±11.83)and(69.46±10.16)points,which were higher than those of(58.22±10.14),(67.27±11.13),(59.04±10.23),(57.28±10.05),(65.07±10.28),(58.36±10.18),(59.65±10.65)and(60.

关 键 词：儿童神经系统慢性疾病 癫痫 左乙拉西坦 奥卡西平 

分 类 号：R742.1[医药卫生—神经病学与精神病学]